Teladoc Health Names Chuck Divita as CEO

Go back to Teladoc Health Names Chuck Divita as CEO

BofA Securities Reiterates Neutral Rating on Teladoc (TDOC)

June 11, 2024 5:28 AM EDT

BofA Securities analyst Allen Lutz reiterated a Neutral rating and $13.50 price target on Teladoc (NYSE: TDOC).

The analyst comments "Filling the CEO role will likely remove the overhang that has been driving investor questions on who will lead the company through the next phase of growth. Mr. Divita has broad experience driving growth and advancing new models... More

Citi Reiterates Neutral Rating on Teladoc (TDOC)

June 10, 2024 8:29 AM EDT

Citi analyst Daniel Grosslight reiterated a Neutral rating and $15.50 price target on Teladoc (NYSE: TDOC).

The analyst comments "We had a chance to catch-up with TDOC mgmt this morning after the company announced Chuck Divita will be joining as CEO (LINK, 6/10). Chuck... More